Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.

摘要: BACKGROUND Clobetasol propionate 0.05% spray is available for treating moderate-to-severe plaque psoriasis; however, there limited information with psoriasis of the scalp. OBJECTIVE Evaluate efficacy, safety, and quality-of-life impact clobetasol in patients moderate to severe METHODS Multicenter, randomized, double-blind, vehicle-controlled study involving 81 men women (Global Severity Score [GSS] = 3 or 4) Eligible were treated vehicle spray, which was applied twice daily up four weeks. The primary efficacy end point GSS scalp after Safety assessments included local tolerability, presence Cushing's syndrome, adverse events. RESULTS At treatment, 85 percent (35/41) group achieved success (GSS clear almost clear), compared 13 (5/40) (P less than .001). proportion who a rating 0) two weeks at treatment 12 51 percent, respectively. well tolerated, no serious events reported cases folliculitis syndrome. CONCLUSION Treatment effective tolerated